IC
MRTX

Ikarian Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Ikarian Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,300
Closed -$191K – 216
2021
Q4 		$191K Hold
1,300
– – 0.03% 161
2021
Q3 		$231K Buy
+1,300
New +$209K 0.02% 201
2021
Q2 		– Sell
-162,000
Closed -$27.8M – 311
2021
Q1 		$27.8M Buy
+162,000
New +$32.1M 0.93% 24
2020
Q4 		– Sell
-549,000
Closed -$91.2M – 257
2020
Q3 		$91.2M Buy
549,000
+399,000
+266% +$54.6M 6.6% 2
2020
Q2 		$17.1M Buy
150,000
+1,100
+0.7% +$107K 1.36% 18
2020
Q1 		$11.4M Buy
148,900
+100,000
+204% +$8.97M 0.86% 28
2019
Q4 		$6.3M Buy
+48,900
New +$4.72M 1.02% 31

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Ikarian Capital's MRTX Position: Q2 2023 in Review

Ikarian Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 33,100 shares — an estimated $1.23M sold.

Ikarian Capital first reported a position in MRTX in Q3 2020 and held it in 4 quarters. The position peaked at $6.4M in Q3 2020. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Ikarian Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ikarian Capital sold 33,100 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $1.23M.
  • Ikarian Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • Ikarian Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $6.4M in Q3 2020.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Ikarian Capital's 13F filing for Q2 2023, filed 14 Aug 2023.